SCHEMBL2082331

SCHEMBL2082331

CCCCCCCCC(=O)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 8/20 1.00
NPC1 O15118 1/20 0.70
RAB9A P51151 1/20 0.70
HTR7 P34969 1/20 0.59
STS P08842 4/20 0.58
HTT P42858 2/20 0.57
DPP4 P27487 1/20 0.57
ALDH1A1 P00352 2/20 0.57
KDM4E B2RXH2 1/20 0.57
ABL1 P00519 1/20 0.57
POLB P06746 1/20 0.57
ALPI P09923 1/20 0.57
GAA P10253 1/20 0.57
ALPG P10696 1/20 0.57
APEX1 P27695 1/20 0.57
CASP3 P42574 1/20 0.57
RECQL P46063 1/20 0.57
BLM P54132 1/20 0.57
CASP7 P55210 1/20 0.57
CASP6 P55212 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2720252 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL27878550 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL1751770 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL26133711 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL11567883 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL1464079 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL28560063 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL4776206 1.00 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL1919198 0.98 HSD17B3 (1.00) HSD17B3NPC1RAB9AHTR7STS
SCHEMBL10586700 0.95 HSD17B3 (0.90) HSD17B3NPC1RAB9AHTR7STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3775104-B2 A METHOD FOR PRODUCING A MIXTURE OF HYDROCARBONS NESTE OYJ (FI) 2026-01-21 EP disclosed
US-20240343680-A1 PROCESS FOR PREPARING ACYL DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-10-17 US disclosed
CN-118103344-A Process for preparing acyl derivatives 国家科学研究中心 2024-05-28 CN disclosed
EP-3898895-B1 METHOD TO PRODUCE HIGH QUALITY COMPONENTS FROM RENEWABLE RAW MATERIAL NESTE OYJ (FI) 2024-05-01 EP disclosed
CN-110777132-B Alpha-amylase combination variants 丹尼斯科美国公司 2024-03-22 CN disclosed
US-20230357643-A1 METHOD FOR UPGRADING LIQUEFIED WASTE PLASTICS NESTE OYJ (FI) 2023-11-09 US disclosed
US-11773334-B2 Method for producing a mixture of hydrocarbons NESTE OYJ (FI) 2023-10-03 US disclosed
EP-3775104-B1 A METHOD FOR PRODUCING A MIXTURE OF HYDROCARBONS NESTE OYJ (FI) 2023-06-21 EP disclosed
WO-2023073080-A1 PROCESS FOR PREPARING ACYL DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-05-04 WO disclosed
CN-113631688-B Process and feed for the production of hydrocarbons 耐思特公司 2023-04-04 CN disclosed
US-5935708-A USE IN DETERGENTS, CLEANING AGENTS, AND BLEACHES; STORAGE STABILITY DEGUSSA AKTIENGESELLSCHAFT (DE) 1999-08-10 US disclosed
US-5859067-A PREPARING BIS(2-HYDROXY-1-NAPHTHYL)DECANE FROM THE CORRESPONDING DIACID; FORMING ACID DICHLORIDE; TREATING WITH 2-NAPHTHOL; REARRANGEMENT; REDUCTION; INHIBITS ACTION OF ADENOSINE TRIPHOSPHATASE ROUFOGALIS BASIL DON (AU) 1999-01-12 US disclosed
US-5741821-A PHENOLIC ENZYME INHIBITORS THE UNIVERSITY OF SYDNEY (AU) 1998-04-21 US disclosed
CN-1124922-A Use of natural products and related synthetic compounds for the treatment of cardiovascular diseases UNIV SYDNEY (AU) 1996-06-19 CN disclosed
WO-1994028886-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1994-12-22 WO disclosed
CN-1024424-C Process and device for machine-washing of linen with particulate product PORCTER & GAMBLE CO (US) 1994-05-04 CN disclosed
CN-1048245-A Carry out the technology and the device of machine-washing linen with the particle shape product PORCTER & GAMBLE CO (US) 1991-01-02 CN disclosed
EP-0057440-B1 AMINOPYRIMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND FUNGICIDAL, INSECTICIDAL AND ACARICIDAL COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1985-05-22 EP disclosed
US-4435402-A Aminopyrimidine derivatives, processes for their preparation, and fungicidal, insecticidal and acaricidal compositions containing them SANKYO COMPANY, LIMITED (JP) 1984-03-06 US disclosed
EP-0057440-A1 Aminopyrimidine derivatives, processes for their preparation, and fungicidal, insecticidal and acaricidal compositions containing them SANKYO COMPANY LIMITED (JP) 1982-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343680-A1 PROCESS FOR PREPARING ACYL DERIVATIVES CYP2B6, ACSS2, GNPAT HSD17B3 744/4885NPC1 1463/4885RAB9A 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.